首页> 外国专利> FORM III CRYSTALLINE R-(R*,R*)-2-(4-FLUOROPHENYL)-BETA,DELTA-DIHYDROXY-5-(1-METHYL-ETHYL)-3-PHENYL-4-(PHENYLAMINO)-CARBONYL-1H-PYRROLE-1H-HEPTANOIC ACID HEMI CALCIUM SALT HYDRATE (ATORVASTATIN HYDRATE) AND PHARMACEUTICAL COMPOSITION CONTAINING IT

FORM III CRYSTALLINE R-(R,R)-2-(4-FLUOROPHENYL)-BETA,DELTA-DIHYDROXY-5-(1-METHYL-ETHYL)-3-PHENYL-4-(PHENYLAMINO)-CARBONYL-1H-PYRROLE-1H-HEPTANOIC ACID HEMI CALCIUM SALT HYDRATE (ATORVASTATIN HYDRATE) AND PHARMACEUTICAL COMPOSITION CONTAINING IT

机译：晶型CRYSTALLINE [R-（R *，R *）]-2-（4-氟代苯基）-BET，δ-二羟基-5-（1-甲基-乙基）-3-苯基-4-[[苯基氨基）-碳] -1H-吡咯-1H-庚酸半水合碳酸钙盐（阿托伐他汀水合物）及其药物成分

页面导航

摘要
著录项
相似文献

摘要

The present invention provides [R- (R *, R *)] - 2- (4-fluorophenyl) -β, dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenyl (amino) carbonyl] -1H-pyrrole-1-heptanecarboxylic acid hemicalcium salt, designated Form III, for use in the manufacture of a medicament for the treatment of hyperlipidemia and hypercholesterolemia. The advantage of the crystalline form according to the invention over the previously known amorphous form is that it has a higher astability with the same or better bioavailability, but at the same time has a more favorable production property, such as filterability. ŕ

机译：本发明提供了[R-（R *，R *）]-2-（4-氟苯基）-β，二羟基-5-（1-甲基乙基）-3-苯基-4-[（苯基（氨基）羰基] -1H-吡咯-1-庚烷羧酸半钙盐，称为晶型III，用于制造用于治疗高脂血症和高胆固醇血症的药物，本发明的结晶形式优于先前已知的无定形形式的优点是same在具有相同或更好的生物利用度的情况下具有较高的稳定性，但同时具有更好的生产性能，例如过滤性。

著录项

公开/公告号HU223598B1

专利类型
公开/公告日2004-10-28

原文格式PDF
申请/专利权人 WARNER-LAMBERT CO. MORRIS PLAINS;
展开▼

申请/专利号HU19990001687
发明设计人 MCKENZIE ANN T.;
展开▼

申请日1996-07-08
分类号C07D207/34;
国家 HU
入库时间 2022-08-21 23:10:50

相似文献

专利
中文文献